Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study

Paccagnella, Adriano; Ghi, Maria Grazia; Loreggian, L.; Buffoli, Alberto; Koussis, Haralabos; Mione, C.A.; Bonetti, Andrea; Campostrini, Franco; Gardani, G; Ardizzoia, Antonio; Dondi, Davide; Guaraldi, M.; Cavallo, Rossella; Tomio, L.; Gava, Alessandro

doi:10.1093/annonc/mdp573

Cited by 167 publications

(137 citation statements)

References 18 publications

Supporting

Mentioning

124

Contrasting

Unclassified

Order By: Relevance

“…Despite that, our Abbreviations: 2nd prim, second primary tumor; CI, confidence interval; DF, distant failure; EFS, event-free survival; LRF, locoregional failure; OS, overall survival. results were favorable in comparison with the 2-year survival data in randomized trials in the HPV-negative cohorts, which range from 48% to 68%, and HPV unknown patients treated with CCRT or CCRT preceded by TPF range from 57% to 61% [48][49][50].…”

Section: Discussionmentioning

confidence: 99%

Helical Tomotherapy in Head and Neck Cancer: A European Single-Center Experience

Gestel¹,

Weyngaert

Kerf³

et al. 2015

The Oncologist

View full text Add to dashboard Cite

Background. We report on a retrospective analysis of 147 patients with early and locoregionally advanced squamous cell head and neck cancer (SCCHN) treated with helical tomotherapy (HT). Patients and Methods. Included were patients with SCCHN of the oral cavity (OC), oropharynx (OP), hypopharynx (HP), or larynx (L) consecutively treated in one radiotherapy center in 2008 and 2009.The prescribed HT dose was 60-66 Gy in the postoperative setting (group A) and 66-70 Gy when given as primary treatment (group B). HT was given alone, concurrent with systemic therapy (ST), that is, chemotherapy, biotherapy, or both, and with or without induction therapy (IT). Acute and late toxicities are reportedusing standard criteria; locoregional failure/progression (LRF), distant metastases (DM), and second primary tumors (SPT) were documented, and event-free survival (EFS) and overall survival (OS) were calculated from the start of HT.

show abstract

Section: Discussionmentioning

confidence: 99%

Helical Tomotherapy in Head and Neck Cancer: A European Single-Center Experience

Gestel¹,

Weyngaert

Kerf³

et al. 2015

The Oncologist

View full text Add to dashboard Cite

show abstract

“…Despite much interest in the use of induction CT, well-designed studies have found no improvement in overall survival with induction CT followed by chemoradiation versus chemoradiation alone (DeCIDE study [64], PARADIGM study [65]). Everolimus is being tested as part of a Phase I/II study (CAPRA) investigating induction CT with weekly everolimus plus carboplatin and paclitaxel in unresectable or inoperable locally advanced SCCHN (NCT01333085).…”

Section: Mtor Inhibitionmentioning

confidence: 99%

Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck

2015

View full text Add to dashboard Cite

“…However, results from two randomized studies directly comparing concurrent chemoradiotherapy with induction chemotherapy plus chemoradiotherapy provide preliminary support for a possible clinical benefit of adding induction chemotherapy to concomitant chemoradiotherapy in unresectable, locally advanced SCCHN patients. In one of those studies, patients received two cycles of PF during radiotherapy (66 -70 Gy), either alone or preceded by three cycles of TPF every 3 weeks [12]. Tumor response rates after completion of chemoradiotherapy were higher among patients receiving induction chemotherapy, and this approach did not compromise the administration of subsequent treatment.…”

Section: Current Questionsmentioning

confidence: 99%

Induction Chemotherapy for Head and Neck Cancer: Recent Data

Vokes

2010

The Oncologist

View full text Add to dashboard Cite

The addition of chemotherapy to radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck (SCCHN) patients improves survival. Meta-analyses of randomized trials have indicated that the benefit of this approach is associated with the timing of chemotherapy administration. It has been demonstrated that the greatest survival benefit over locoregional treatment alone is seen with the concurrent administration of chemotherapy and radiotherapy. However, sequential chemotherapy administration, in the form of induction chemotherapy followed by radiotherapy or concurrent chemoradiotherapy, has been successful as a strategy for organ function preservation in patients with potentially resectable SCCHN. In addition, a meta-analysis of trials using platinum and 5-fluorouracil (PF)-containing induction regimens demonstrated a significant survival benefit for this approach over locoregional treatment alone in locally advanced disease. In recent years, the introduction of the taxanes into induction chemotherapy has provided physicians with more active regimens. The triplet combination induction regimen of docetaxel, cisplatin, and 5-fluorouracil has been shown to be more effective in prolonging survival than the doublet PF. Current trials are testing whether the addition of induction chemotherapy to standard concomitant chemoradiotherapy is superior to concomitant chemoradiotherapy alone. The Oncologist 2010;15(suppl 3):3-7

show abstract

Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study

Abstract: Induction TPF followed by CT/RT was associated with higher radiologic CR in patients with locally advanced SCCHN with no negative impact on CT/RT feasibility.

Cited by 167 publications

References 18 publications

Helical Tomotherapy in Head and Neck Cancer: A European Single-Center Experience

Helical Tomotherapy in Head and Neck Cancer: A European Single-Center Experience

Targeting the PI3K/AKT/mTOR pathway in squamous cell carcinoma of the head and neck

Induction Chemotherapy for Head and Neck Cancer: Recent Data

Contact Info

Product

Resources

About